SLC5A2 and hydrops fetalis: The efficacy of the sodium-glucose transporter 2 (SGLT-2) class of inhibitors in reducing MACE in diabetic patients is strongly supported by the findings of several randomized large-scale clinical trials (EMPA-REG OUTCOME, CANVAS, DAPA-HF, DECLARE-TIMI, VERTIS-CV) [5,9,29,30,31].